Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene

Overview

The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1 gene. Moreover, the study evaluates ABCB1-genotype dependent side-effects of approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1 gene.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Masking: Double (Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 2014

Interventions

  • Drug: Paroxetine
  • Drug: Sertraline
  • Drug: Citalopram
  • Drug: Venlafaxine
  • Drug: Amitriptyline
  • Drug: Escitalopram
  • Drug: Amitriptylinoxide
  • Drug: Nortriptyline
  • Drug: Trimipramine

Arms, Groups and Cohorts

  • Experimental: Normal dosage
    • Selected antidepressants that are substrates of the P-glycoprotein: Dosage: paroxetine < 40 mg/d sertraline < 100 mg/d citalopram < 40 mg/d escitalopram < 20 mg/d venlafaxine < 225 mg/d amitriptyline < 150 mg/d amitriptylinoxide < 150 mg/d nortriptyline < 150 mg/d trimipramine < 150 mg/d
  • Experimental: High dosage
    • Selected antidepressants that are substrates of the P-glycoprotein: Dosage: paroxetine < 80 mg/d sertraline < 200 mg/d citalopram < 80 mg/d escitalopram < 40 mg/d venlafaxine < 450 mg/d amitriptyline < 300 mg/d amitriptylinoxide < 300 mg/d nortriptyline < 300 mg/d trimipramine < 300 mg/d

Clinical Trial Outcome Measures

Primary Measures

  • 25% improvement in the HAM-D
    • Time Frame: after 28 days of treatment
    • Partial response indicated by at least 25% improvement in the Hamilton Rating Scale for Depression (HAM-D)

Secondary Measures

  • side effects
    • Time Frame: after 28 days of treatment
    • UKU side effect scale, AMDP side effect scale

Participating in This Clinical Trial

Inclusion Criteria

  • Male and female patients – Age between 18 and 80 years – Inpatients with a DSM-IV diagnosis of Major Depression – single episode or recurrent – moderate to severe intensity – without psychotic features – Inpatients with a DSM-IV diagnosis of bipolar disorder I or II – current episode with depressive symptoms – moderate to severe intensity – without psychotic features – HAM-D score at the time of inclusion in the study ≥ 14 – Patient has already been adjusted to one of the following antidepressants in a dose which is still under the defined normal-dose: – paroxetine < 40 mg/d – sertraline < 100 mg/d – citalopram < 40 mg/d – escitalopram < 20 mg/d – venlafaxine < 225 mg/d – amitriptyline < 150 mg/d – amitriptylinoxide < 150 mg/d – nortriptyline < 150 mg/d – trimipramine < 150 mg/d Exclusion Criteria:

  • Acute suicidality (HAM-D Item 3 score > 2) – Acute alcohol-, hypnotics-, analgesics- or psychopharmacological intoxication or delirium – Current alcohol dependence, or dependencies from other psychotropic substances – Severe medical or neurological diseases: patients with severe hepatic (severe impairment of liver function, cirrhosis of the liver), renal (kidney malfunctions), cardiovascular (recent myocardial infarction, instable heart disease), neurological diseases (e.g. multiple sclerosis, Parkinson, dementia) – Patients incapable of giving informed consent – Pregnant or breast-feeding women – Women of reproductive age without effective contraception – Simultaneous participation in other clinical trials or participation in an other clinical trial within 6 weeks before the start of the study – Hypersensitivity to the study medication or to one of the ingredients of the medication – Simultaneous treatment with another antidepressant besides study medication (exception: trazodone up to 75 mg/d, mirtazapine up to 15 mg/d, trimipramine up to 50 mg/d) – Simultaneous treatment with mood stabilizers or neuroleptic drugs (exception: quetiapine up to 50 mg/d, olanzapine up to 5 mg/d) Exclusion criteria of the study medication

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 79 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • HolsboerMaschmeyer NeuroChemie GmbH
  • Collaborator
    • Max-Planck-Institute of Psychiatry
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Florian Holsboer, MD, PHD, Principal Investigator, Max-Planck-Institute of Psychiatry
  • Overall Contact(s)
    • Barbara Breitenstein, MSc, 0049 89 30622, barbara_breitenstein@mpipsykl.mpg.de

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.